🔥 Thursday 30 January 2025 Thu, 30 Jan 2025

Aldoro Resources has confirmed extensive niobium mineralisation at its Kameelburg project in Namibia, prompting an expansion of its diamond drilling program ahead of a maiden resource estimate expected in Q2 2025.

Karoon Energy delivered a record full-year sales revenue of US$776.5 million in 2024 despite a slight production dip in the final quarter. The company’s revised resource estimates and plans to acquire the Baúna FPSO signal a pivotal phase for its growth trajectory.

Murray Cod Australia Ltd has secured a $43 million funding package from Westpac, advancing its Stanbridge site construction and expanding its biomass. The company also initiated exports to Thailand and is progressing towards entry into the Chinese market.

Nickel Industries delivered a record US$72.4 million EBITDA in Q4 2024, driven by strong operational milestones and strategic project advancements. However, currency fluctuations posed a significant challenge, underscoring the company’s exposure to foreign exchange risks.

Prodigy Gold's December 2024 quarterly report reveals significant high-grade gold intercepts at its Hyperion and Tregony projects, alongside progress on metallurgical testing and a new Mineral Lease application. The company maintains a solid cash position with no debt, positioning itself for an active 2025 exploration season.

FirstWave reports a stable Q2 FY25 with no cash burn for the second consecutive quarter, maintaining cash reserves at $1.68 million while securing key client contract renewals and launching a promising new product.

MRG Metals reports significant progress in its Mozambique Heavy Mineral Sands joint venture with Sinowin Lithium, alongside promising rare earth element exploration results in Zimbabwe, positioning the company for potential growth in strategic mineral markets.

Resolute Mining reported a strong operational and financial performance in 2024, producing 340,000 ounces of gold and generating $250 million in operating cash flow. Despite higher costs driven by new mining regulations, the company maintains positive guidance for 2025 with ongoing exploration and development projects across West Africa.

New World Resources Limited has completed a significant reserve definition drilling program at its Antler Copper Project, alongside key permitting progress and accelerated funding discussions, setting the stage for a definitive feasibility study in 2025.

88 Energy Limited announces a maiden internal Prospective Resource estimate of 283 million barrels of oil for its Canning Prospect at Project Leonis, Alaska, with plans to drill the Tiri-1 exploration well targeting multiple reservoirs in 2026.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Kingsgate Consolidated Limited reported a 150% increase in ore mined and a 13.4% rise in gold production for the December 2024 quarter, marking its third consecutive quarter of growth. Despite some challenges with grade control and cost guidance, the company anticipates further production and efficiency gains.

Kingsrose Mining, in alliance with BHP, reports promising high-grade copper and polymetallic discoveries in Norway and Finland, advancing one of Europe’s largest exploration programs.

Nanoveu Limited has appointed industry veteran Mark Goranson as CEO of its Semiconductor Technologies division, positioning the company to accelerate growth in ultra-low-power AI-driven chips following its EMASS acquisition.

Ioneer Ltd has closed a $996 million loan from the U.S. Department of Energy to accelerate its Rhyolite Ridge Lithium-Boron Project in Nevada, following key federal permitting milestones. Construction is targeted for 2025, promising to boost domestic critical mineral supply and create hundreds of jobs.

Syrah Resources faced operational setbacks at its Balama graphite mine due to protests, prompting a force majeure declaration, yet it maintains a robust cash position and advances its downstream Vidalia anode material facility amid growing market demand.

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Godolphin Resources has completed its first phase of drilling at Lewis Ponds, intersecting significant massive and semi-massive sulphide mineralisation that could underpin an upgrade to its existing resource estimate.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

OpenLearning Limited reported a 23% year-on-year increase in SaaS annual recurring revenue to $2.335 million in Q4 FY24, driven by strong growth in AI-powered products and strategic partnerships. The company also cut net operating cash outflows by over half, signaling improved operational efficiency.

GTi Energy has completed drilling two of three groundwater monitoring wells at its Lo Herma ISR Uranium Project, progressing critical infrastructure ahead of aquifer testing and resource development.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.